Second Landmark RCT Evaluating Mirragen in Diabetic Foot Ulcers
In a prospective, multi-centered randomized controlled trial (RCT) involving 100+ patients, wound care physicians evaluated the impact of Mirragen, a borate-based bioactive glass fiber matrix, in the treatment of diabetic foot ulcers (DFUs). The second RCT on DFUs sponsored by Engineered Tissue Solutions (ETS) further illustrates Mirragen’s ability to facilitate the wound healing process in these challenging wounds.
Join us for our lunch symposium, where top wound care experts will delve into the study’s details and explore why Mirragen is an essential addition to your wound care armamentarium.
Event Details
Date: Thursday, May 1, 2025
Time: 12 – 1:30 p.m. (CT)
Location: Gaylord Texan Resort & Convention Center
(Room: Dallas 5 – 7)
Speakers
Marcus Gitterle,
MD
Chief Medical Officer, WoundCentrics, LLC
John Lantis,
MD
Site-Chief of Surgery at the Mount Sinai West Hospital and Professor of Surgery at the Icahn School of Medicine
David Armstrong,
DPM, PhD
Distinguished Professor of Surgery and Neurological Surgery, Director. Southwestern Academic Limb Salvage Alliance (SALSA) at Keck School of Medicine, USC / Director, USC Center to Stream Healthcare in Place
Charles M. Zelen, DPM
Podiatrist at Foot and Ankle Associates
of Southwest Virginia